BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 28612220)

  • 1. Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.
    Heuser M; Gabdoulline R; Löffeld P; Dobbernack V; Kreimeyer H; Pankratz M; Flintrop M; Liebich A; Klesse S; Panagiota V; Stadler M; Wichmann M; Shahswar R; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Geffers R; Schlegelberger B; Göhring G; Kreipe HH; Germing U; Ganser A; Kröger N; Koenecke C; Thol F
    Ann Hematol; 2017 Aug; 96(8):1361-1372. PubMed ID: 28612220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
    Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
    [No Abstract]   [Full Text] [Related]  

  • 4. [Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in the treatment of secondary acute myeloid leukemia].
    Yuan XL; Wu YB; Song XL; Chen Y; Lu Y; Lai XY; Shi JM; Liu LZ; Zhao YM; Yu J; Yang LX; Lan JP; Cai Z; Huang H; Luo Y
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):41-47. PubMed ID: 38527837
    [No Abstract]   [Full Text] [Related]  

  • 5. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
    Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
    Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.
    Hamilton BK; Visconte V; Jia X; Tabarroki A; Makishima H; Hasrouni E; Abounader D; Kalaycio M; Sekeres MA; Sobecks R; Duong Liu H; Bolwell B; Maciejewski JP; Copelan E; Tiu RV
    Am J Hematol; 2016 Jun; 91(4):406-9. PubMed ID: 26799334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.
    Yoshizato T; Nannya Y; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Suzuki H; Nagata Y; Sato Y; Kakiuchi N; Matsuo K; Onizuka M; Kataoka K; Chiba K; Tanaka H; Ueno H; Nakagawa MM; Przychodzen B; Haferlach C; Kern W; Aoki K; Itonaga H; Kanda Y; Sekeres MA; Maciejewski JP; Haferlach T; Miyazaki Y; Horibe K; Sanada M; Miyano S; Makishima H; Ogawa S
    Blood; 2017 Apr; 129(17):2347-2358. PubMed ID: 28223278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Kongtim P; Parmar S; Milton DR; Perez JMR; Rondon G; Chen J; Chilkulwar AR; Al-Atrash G; Alousi A; Andersson BS; Im JS; Hosing CM; Bashir Q; Khouri I; Kebriaei P; Oran B; Popat U; Champlin R; Ciurea SO
    Bone Marrow Transplant; 2019 Jun; 54(6):839-848. PubMed ID: 30258129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): successful management by allogeneic hematopoietic stem cell transplant (HSCT).
    Trobaugh-Lotrario AD; Kletzel M; Quinones RR; McGavran L; Proytcheva MA; Hunger SP; Malcolm J; Schissel D; Hild E; Giller RH
    Bone Marrow Transplant; 2005 Jan; 35(2):143-9. PubMed ID: 15558042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
    Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy.
    Gauthier J; Damaj G; Langlois C; Robin M; Michallet M; Chevallier P; Beguin Y; N'guyen S; Bories P; Blaise D; Cornillon J; Clavert A; Mohty M; Huynh A; Thiébaut-Bertrand A; Vigouroux S; Duhamel A; Yakoub-Agha I
    Transplantation; 2015 Aug; 99(8):1672-80. PubMed ID: 25769079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.
    Della Porta MG; Alessandrino EP; Bacigalupo A; van Lint MT; Malcovati L; Pascutto C; Falda M; Bernardi M; Onida F; Guidi S; Iori AP; Cerretti R; Marenco P; Pioltelli P; Angelucci E; Oneto R; Ripamonti F; Bernasconi P; Bosi A; Cazzola M; Rambaldi A;
    Blood; 2014 Apr; 123(15):2333-42. PubMed ID: 24558201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Outcomes of 138 myelodysplastic syndrome patients with HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation].
    Wang QQ; Liu ZX; Zhao XL; Zhang GX; Yao JF; Zheng XH; Zhang LN; Shen YY; Zhao XL; He Y; Huang Y; Zhang RL; Wei JL; Ma QL; Pang AM; Yang DL; Zhai WH; Jiang EL; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):132-137. PubMed ID: 32135630
    [No Abstract]   [Full Text] [Related]  

  • 16. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.
    Deeg HJ; Scott BL; Fang M; Shulman HM; Gyurkocza B; Myerson D; Pagel JM; Platzbecker U; Ramakrishnan A; Radich JP; Sandmaier BM; Sorror M; Stirewalt DL; Wilson WA; Storb R; Appelbaum FR; Gooley T
    Blood; 2012 Aug; 120(7):1398-408. PubMed ID: 22767498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
    Al-Ali HK; Brand R; van Biezen A; Finke J; Boogaerts M; Fauser AA; Egeler M; Cahn JY; Arnold R; Biersack H; Niederwieser D; de Witte T
    Leukemia; 2007 Sep; 21(9):1945-51. PubMed ID: 17611571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.
    Armand P; Kim HT; DeAngelo DJ; Ho VT; Cutler CS; Stone RM; Ritz J; Alyea EP; Antin JH; Soiffer RJ
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):655-64. PubMed ID: 17531775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (⩾60 years).
    Pohlen M; Groth C; Sauer T; Görlich D; Mesters R; Schliemann C; Lenz G; Müller-Tidow C; Büchner T; Berdel WE; Stelljes M
    Bone Marrow Transplant; 2016 Nov; 51(11):1441-1448. PubMed ID: 27295269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.